In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white patients, according to results presented at the 17th AACR Conference on the Science ...
Sep 21, 2024
1
58
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results, published ...
Sep 19, 2024
0
37
A cancer study has found that certain gut bacteria may influence whether or not a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer.
Sep 5, 2024
0
41
A clinical trial has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants. The phase II clinical trial, NeoACTIVATE, enrolled patients with ...
Jul 11, 2024
0
90
A cutting-edge class of drugs is saving and extending the lives of cancer patients.
Jun 3, 2024
0
21
Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.
Apr 4, 2024
0
36
Patients with triple-negative breast cancer do not benefit from the addition of atezolizumab to their post-surgery chemotherapy treatment, according to the results of a large phase 3 clinical trial presented at the 14th European ...
Mar 19, 2024
0
43
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer types that have lacked such tools until now, according to a new study published in Cancer Immunology ...
Feb 13, 2024
0
50
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers ...
Dec 14, 2023
0
46
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint inhibitor atezolizumab to standard of care with bevacizumab and ...
Dec 4, 2023
0
36
